agilon health (NYSE:AGL) Beats Q2 CY2026 Sales Expectations, Full
Agilon Health (NYSE:AGL) reported Q2 CY2026 revenue of $1.49 billion, up 7.2% year over year, exceeding Wall Street estimates by 2.8%. Next-quarter revenue guidance was $1.46 billion at the midpoint, about 3.7% above expectations. GAAP EPS was $1.04, well above consensus, and the stock rose 2.6% to $110.51.
How this was made
The 30-second read
Why it matters
Q2 CY2026 results beat revenue and EPS consensus, and next-quarter revenue guidance is above expectations, which can drive near-term estimate revisions. However, the article also points to slowing growth and flat forward revenue expectations, which may temper follow-through.
Market read
Traders can reassess AGL’s near-term earnings power and guidance credibility after the reported beat and above-consensus revenue outlook.
What to watch
Customer count is described as declining over the last two years, so traders may focus on whether revenue growth is sustainable without customer growth.
Background
Agilon Health provides a platform for primary care physicians to transition Medicare patients to value-based care via long-term partnerships and global capitation arrangements.
Ticker impact
Agilon Health reported Q2 CY2026 revenue of $1.49B, up 7.2% YoY, and guided next-quarter revenue to $1.46B midpoint above expectations.
Likely supports continued upside bias in the near term, though the article flags slowing demand and flat 12-month revenue expectations.
The text provides concrete Q2 results, next-quarter guidance, and an immediate post-results stock move, but it also notes decelerating growth and weak forward EPS expectations, limiting conviction on sustained upside.
Market effects
A beat in a Medicare-focused value-based care services name may modestly improve sentiment toward healthcare services providers tied to Medicare outcomes.
Primarily US healthcare services sentiment; no specific regional spillover described.
Limited global relevance; the catalyst is company-specific earnings and guidance.
Counterpoint
Despite the beat, the article highlights decelerating demand and expects flat revenue over the next 12 months, which could cap multiple expansion.
Key entities
- companyAgilon Health
Reported Q2 CY2026 revenue and EPS results, plus next-quarter revenue guidance, and discussed customer and margin trends.
